Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
Exenatide
Not assigned in the current dataset.
Retatrutide
Not assigned in the current dataset.
Exenatide and Retatrutide sit closest together within the GLP-1 analog, which gives them a broadly related biological identity. Both are most often discussed in Metabolic and endocrine, which gives the comparison a meaningful common setting even when the rest of their profiles are not identical. Mechanistically, both point toward Receptor agonist and converge on GLP-1 receptor, although the downstream emphasis is not identical. Exenatide has a more venom-derived origin, while Retatrutide is closer to synthetic analog background and their development context also differs, with Exenatide approved while Retatrutide is in Clinical phase 3. Exenatide takes the form of a linear peptide, whereas Retatrutide is closer to a peptide conjugate, while Exenatide carries amidation features, while Retatrutide instead reflects lipidation changes.